Research programme: CC-chemokine receptor 3 antagonists - Bristol-Myers Squibb
Alternative Names: BMS 570520; DIN 106935Latest Information Update: 12 Sep 2008
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action CCR3 receptor antagonists; Ion channel antagonists; Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic rhinitis; Arrhythmias; Asthma
Most Recent Events
- 04 Sep 2008 Discontinued - Preclinical for Allergic rhinitis in USA (unspecified route)
- 04 Sep 2008 Discontinued - Preclinical for Arrhythmias in USA (unspecified route)
- 04 Sep 2008 Discontinued - Preclinical for Asthma in USA (unspecified route)